Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Nalmefene in Healthy Japanese Males
NCT02679469Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nalmefene in alcohol dependence, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Maximum (Peak) Plasma Concentration of the Drug at 72 hours, Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at 72 hours and 1 more. Started Feb 2016; status: completed.
02
Drugs
nalmefene
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NCT02679469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679469.